EpiCast Report: Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma that presents primarily in the lymph nodes
GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and five-year diagnosed prevalent cases forecast in the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized and in case of data scarcity, appropriate proxies were used to fill the data gaps.
In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.
Scope
The Chronic lymphocytic leukemia (CLL) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.
The CLL epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The CLL EpiCast series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global CLL market.
Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
Understand magnitude of CLL population by two staging systems.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.